Home / Nervous system / Remifentanil
ATC N01AH06 · Opioid Anesthetics
Remifentanil shortage
As of 2 Nov 2026, Remifentanil has a reported shortage in 5 of the 15 countries we track (United States, Canada, Czechia, Norway, Australia), covering 15 products from 6 companies.
Countries5/15
Products15packs or presentations
Companies65 listed
Short since22 Jan 20206.8 years ago
Earliest return5 Nov 2026company estimate
Main reasonNot stated
United States9 products shortCanada2 products shortGermanyNo reported shortageFranceNo reported shortageItalyNo reported shortageSpainNo reported shortageIrelandNo reported shortageAustriaNo reported shortageBelgiumNo reported shortageSwitzerlandNo reported shortageCzechia1 product shortNorway1 product shortSwedenNo reported shortageJapanNo reported shortageAustralia2 products short
Timeline
United StatesCanadaCzechiaNorwayAustralia
Solid bars run from the reported start to today; faded bars show the time left until the expected return. An arrow means no return date was given.
Which companies are short
products short, all countriesListed: Hikma HIK · LSE, Fresenius Kabi FRE · Xetra, Viatris VTRS · Nasdaq, Teva TEVA · NYSE / TASE, Aspen APN · JSE
Compared with similar medicines
ATC group N01AH · Opioid AnestheticsAffected products
| Country | Product | Company | Since | Expected back | Reason |
|---|---|---|---|---|---|
| US | Remifentanil Hydrochloride, Injection, 1 mg per vial (NDC 0143-9391-10) | Hikma Pharmaceuticals USA, Inc. | 28 Jun 2022 | not given | Increased demand Demand increase for the drug |
| US | Remifentanil Hydrochloride, Injection, 1 mg/1 mL (NDC 63323-723-03) | Fresenius Kabi USA, LLC | 28 Jun 2022 | not given | Distribution or logistics Delay in shipping of the drug |
| US | Remifentanil Hydrochloride, Injection, 1 mg/1 mL (NDC 63323-724-05) | Fresenius Kabi USA, LLC | 28 Jun 2022 | not given | Not stated |
| US | Remifentanil Hydrochloride, Injection, 1 mg/1 mL (NDC 63323-725-10) | Fresenius Kabi USA, LLC | 28 Jun 2022 | not given | Not stated |
| US | Remifentanil Hydrochloride, Injection, 2 mg per vial (NDC 0143-9392-10) | Hikma Pharmaceuticals USA, Inc. | 28 Jun 2022 | not given | Increased demand Demand increase for the drug |
| US | Remifentanil Hydrochloride, Injection, 5 mg per vial (NDC 0143-9393-10) | Hikma Pharmaceuticals USA, Inc. | 28 Jun 2022 | not given | Increased demand Demand increase for the drug |
| US | Ultiva, Injection, 1 mg/1 mL (NDC 72078-034-01) | Mylan Institutional, a Viatris Company | 28 Jun 2022 | not given | Not stated |
| US | Ultiva, Injection, 2 mg (NDC 72078-035-02) | Mylan Institutional, a Viatris Company | 28 Jun 2022 | not given | Not stated |
| US | Ultiva, Injection, 5 mg (NDC 72078-036-05) | Mylan Institutional, a Viatris Company | 28 Jun 2022 | not given | Not stated |
| CA | REMIFENTANIL FOR INJECTION (10pk) | TEVA CANADA LIMITED | 22 Jan 2020 | not given | Manufacturing problem Disruption of the manufacture of the drug |
| CA | REMIFENTANIL FOR INJECTION (10pk) | TEVA CANADA LIMITED | 22 Jan 2020 | not given | Manufacturing problem Disruption of the manufacture of the drug |
| CZ | REMIFENTANIL B. BRAUN 1MG 1MG INJ/INF PLV CSL 5 | B. Braun Melsungen AG, Melsungen | 7 Oct 2026 | 5 Nov 2026 | Manufacturing problem Výrobní důvody |
| NO | Ultiva 1 mg pulver til injeksjons-/infusjonsvæske, oppløsning, 5x1 mg hetteglass | Aspen Pharma Trading Limited | 1 Mar 2026 | 31 Dec 2026 | Commercial decision or withdrawal Kommersielle grunner |
| AU | Remifentanil-AFT, remifentanil (as hydrochloride) 1 mg, powder for injection, glass vial | 16 Oct 2026 | 16 Jan 2027 | Not stated | |
| AU | REMIFENTANIL VIATRIS 1mg remifentanil (as hydrochloride) powder for injection vial anticipated | 11 Dec 2026 | 20 Jan 2027 | Not stated |
"Expected back" is the date the company gave the authority, when it gave one. Ask a pharmacist about alternatives.